DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis Dtsch Med Wochenschr 2012; 137(40): 2026-2028DOI: 10.1055/s-0032-1305308 Pneumologie | Commentary Pneumologie © Georg Thieme Verlag KG Stuttgart · New YorkPulmonale HypertoniePulmonary Hypertension G. Kovacs 1 Medizinische Universität Graz, Pulmonologie; Ludwig Boltzmann Institut für Lungengefäßforschung , H. Olschewski 1 Medizinische Universität Graz, Pulmonologie; Ludwig Boltzmann Institut für Lungengefäßforschung› InstitutsangabenArtikel empfehlen Abstract Artikel einzeln kaufenSchlüsselwörter Schlüsselwörterpulmonale Hypertonie - aktuelle Studien - frühe Therapie Keywords Keywordspulmonary hypertension - actual studies - early therapy Volltext Referenzen Literatur 1 Chung L, Liu J, Parsons L et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394 2 Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157 3 Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS), endorsed by the international society of heart and lung transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537 4 Guazzi M, Vicenzi M, Arena R et al. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164-174 5 Kovacs G, Maier R, Aberer E et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012; 64: 1257-1762 6 Seimetz M, Parajuli N, Pichl AN et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147: 293-305 7 Simonneau G, Torbicki A, Hoeper MM et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; Feb 23. 8 Tapson VF, Torres F, Kermeen F et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; May 24 [Epub ahead of print]
